Table of Contents
Chapter One: Executive Summary
- Background
- Scope and Methodology
- Size and Growth of Market
- Market Trends and Factors
Chapter Two: Introduction
- Background
- Population Demographics
- Epidemiology and Pathology of Rheumatoid Arthritis
Chapter Three: Rheumatoid Arthritis Therapeutics
- Current Approaches
- Approaches to Rheumatoid Arthritis Therapy
- Patient Education
- Rest and Exercise
- Diet
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Steroids (Corticosteroids, Glucocorticoids)
- Cytokine Targeted Therapy
- Other Approaches
- Emerging Therapeutic Approaches
- Tumor Necrosis Factor-a (TNF-a) Inhibitors
- Interleukin-1 (IL-1)Inhibitors
- p38 MAP Kinase Inhibitors
- Interleukin-6 (IL-6) Inhibitors
- Interleukin-15 (IL-15) Inhibitors
- HC-gp-39 (Human Cartilage-glycoprotein-39) Desensitizers
- C5 (Complement) Inhibitors
- Vaccines
- Other Approaches
Chapter Four: Market Analysis
- Market Size and Growth
- Competitive Outlook
- Market Trends
Chapter Five: Company Profiles
- Overview
- Abbott Laboratories
- AstraZeneca
- Biogen, Inc.
- Chugai Pharmaceuticals USA, LLC
- Corixa Corporation
- Fujisawa Pharmaceutical Co., Ltd.
- Lifestyle Therapeutics - Camrose, Inc.
- Medarex, Inc.
- Pfizer
- Schering-Plough
- Vertex Pharmaceuticals, Inc.
- Viron Therapeutics, Inc.
- Wyeth
Chapter Six: Conclusions and Strategic Implications
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- Ninth Conclusion
- Tenth Conclusion
APPENDIX A: Company Directory
List of Exhibits
Chapter One: Executive Summary
- Table 1-1: Estimated TAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets, 2003-2013
- Table 1-2: Estimated SAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets 2003-2013
- Figure 1-1: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the Middle-Aged and Elderly Market Segments 2003-2013
- Figure 1-2: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 45- to 54-Year-Old Market Segment 2003-2013
- Figure 1-3: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 55- to 64-Year-Old Market Segment 2003-2013
- Figure 1-4: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 65- to 74-Year-Old Market Segment 2003-2013
- Figure 1-5: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 75+ Year-Old Market Segment 2003-2013
Chapter Two: Introduction
- Figure 2-1: Growth of the Worldfs Elderly (60+ Years) Population 2001-2025
- Figure 2-2: Population Distribution of the United States by Age and Sex 1999 and 2025
- Figure 2-3: The Growing United States Population 2003-2013
- Figure 2-4: Increasing Median Age of the United States Population
- Figure 2-5: Increasing Mean Age of the United States Population
- Table 2-1: Aging of the United States Population in the Age Groups 45 Years and Older 2003-2013
- Figure 2-6: Aging Trends in the United States Population for the Age
- Groups 45 Years and Older 2003-2013
- Figure 2-7: Changes in the Composition of the 45+Year-Old and Older Age Segment in the United States 2003 and 2013
- Table 2-2: Older Population Groups as Percentages of the Total United States Population by Age Group 2003-2013
- Figure 2-8: Aging Trends by Percentage of the United States Population for the Age Groups 45 Years and Older 2003-2013
- Table 2-3: Prevalence of Rheumatoid Arthritis Cases in the United States
- for the Total Population and Those 45 Years of Age and Older 2003-2013 Figure 2-9: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group 2003-2013
Chapter Three: Rheumatoid Arthritis Therapeutics
- Table 3-1: Currently Marketed Products for the Treatment of Rheumatoid Arthritis
- Table 3-2: Recommended Patient Monitoring for the Administration of DMARDS in the Treatment of Rheumatoid Arthritis Table 3-3: Rheumatoid Arthritis Therapeutics in Development
Chapter Four: Market Analysis
- Table 4-1: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
- Figure 4-1: Trending in the United States Total and Serviceable
- Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
- Table 4-2: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics in the 45+ Age Population 2003-2013
- Figure 4-2: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 45- to 54-Year-Old Age Group 2003-2013
- Figure 4-3: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 55- to 64-Year-Old Age Group 2003-2013
- Figure 4-4: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
- Figure 4-5: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
- Table 4-6: Currently Marketed and Potential Competitive Products for the Treatment of Rheumatoid Arthritis
|
Related Report
|
View Cart
